PAQR3: A novel tumor suppressor gene

American Journal of Cancer Research

Volumn 5, Issue 9, 2015, Pages 2562-2568

  Yu, Xin ^a   Li, Zheng ^a   Chan, Matthew T V ^b   Wu, William Ka Kei ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; miRNAs; PAQR3; Tumor suppressor

Indexed keywords

MICRORNA; PROTEIN PAQR3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BLADDER CANCER; CARCINOGENESIS; DOWN REGULATION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; OSTEOSARCOMA; PAQR3 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SKIN CARCINOGENESIS; STOMACH CANCER; STRUCTURE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 84991380542     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol 2009; 472: 57-88.
2. Farazi TA, Spitzer JI, Morozov P and Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
3. Ferguson LR, Tatham AL, Lin Z and Denny WA. Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets 2011; 11: 199-212.
4. Wang X, Li X, Fan F, Jiao S, Wang L, Zhu L, Pan Y, Wu G, Ling ZQ, Fang J and Chen Y. PAQR3 plays a suppressive role in the tumorigenesis of colorectal cancers. Carcinogenesis 2012; 33: 2228-2235.
5. Ma Z, Wang Y, Piao T, Li Z, Zhang H, Liu Z and Liu J. The tumor suppressor role of PAQR3 in osteosarcoma. Tumour Biol 2015; 36: 3319-24.
6. Wang X, Wang L, Zhu L, Pan Y, Xiao F, Liu W, Wang Z, Guo F, Liu Y, Thomas WG and Chen Y. PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110alpha to the Golgi apparatus. Diabetes 2013; 62: 444-456.
7. Wang L, Wang X, Li Z, Xia T, Zhu L, Liu B, Zhang Y, Xiao F, Pan Y, Liu Y, Guo F and Chen Y. PAQR3 has modulatory roles in obesity, energy metabolism, and leptin signaling. Endocrinology 2013; 154: 4525-4535.
8. Villa NY, Moussatche P, Chamberlin SG, Kumar A and Lyons TJ. Phylogenetic and preliminary phenotypic analysis of yeast PAQR receptors: potential antifungal targets. J Mol Evol 2011; 73: 134-152.
9. Villa NY, Kupchak BR, Garitaonandia I, Smith JL, Alonso E, Alford C, Cowart LA, Hannun YA and Lyons TJ. Sphingolipids function as downstream effectors of a fungal PAQR. Mol Pharmacol 2009; 75: 866-875.
10. Tang YT, Hu T, Arterburn M, Boyle B, Bright JM, Emtage PC and Funk WD. PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif. J Mol Evol 2005; 61: 372-380.
11. Gonzalez-Velazquez W, Gonzalez-Mendez R and Rodriguez-del Valle N. Characterization and ligand identification of a membrane progesterone receptor in fungi: existence of a novel PAQR in Sporothrix schenckii. BMC Microbiol 2012; 12: 194.
12. Zhu D, Zhang J, Bin Y, Xu C, Shen J and Matsuo M. Dielectric studies on the heterogeneity and interfacial property of composites made of polyacene quinone radical polymers and sulfonated polyurethanes. J Phys Chem A 2012; 116: 2024-2031.
13. Svensk E, Stahlman M, Andersson CH, Johansson M, Boren J and Pilon M. PAQR-2 regulates fatty acid desaturation during cold adaptation in C. elegans. PLoS Genet 2013; 9: e1003801.
14. Pilon M and Svensk E. PAQR-2 may be a regulator of membrane fluidity during cold adaptation. Worm 2013; 2: e27123.
15. Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J and Lopez JA. Novel progesterone receptors: neural localization and possible functions. Front Neurosci 2013; 7: 164.
16. Morrill GA, Kostellow AB and Gupta RK. A computational analysis of non-genomic plasma membrane progestin binding proteins: signaling through ion channel-linked cell surface receptors. Steroids 2013; 78: 1233-1244.
17. Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J and Lopez JA. Nonclassical progesterone signalling molecules in the nervous system. J Neuroendocrinol 2013; 25: 991-1001.
18. Ndiaye K, Poole DH, Walusimbi S, Cannon MJ, Toyokawa K, Maalouf SW, Dong J, Thomas P and Pate JL. Progesterone effects on lymphocytes may be mediated by membrane progesterone receptors. J Reprod Immunol 2012; 95: 15-26.
19. Charles NJ, Thomas P and Lange CA. Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer 2010; 1: 167-176.
20. Flock GB, Cao X, Maziarz M and Drucker DJ. Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in mice. Diabetes 2013; 62: 283-290.
21. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM and McCubrey JA. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-164.
22. Li J, Zhao Z, Liu J, Huang N, Long D, Wang J, Li X and Liu Y. MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells through delicate interaction with TGF-beta1/Smads pathway. Cell Prolif 2010; 43: 333-343.
23. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L and Martelli AM. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3: 1068-1111.
24. Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, Bai O, Liu W, Xie X, Wang Z, Fang J and Chen Y. RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. Oncogene 2010; 29: 5404-5415.
25. Appleton CT, Usmani SE, Mort JS and Beier F. Rho/ROCK and MEK/ERK activation by transforming growth factor-alpha induces articular cartilage degradation. Lab Invest 2010; 90: 20-30.
26. Li Z, Shen J, Wu WK, Yu X, Liang J, Qiu G and Liu J. Leptin induces cyclin D1 expression and proliferation of human nucleus pulposus cells via JAK/STAT, PI3K/Akt and MEK/ERK pathways. PLoS One 2012; 7: e53176.
27. Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y, Wang Z and Chen Y. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells. Carcinogenesis 2008; 29: 1157-1163.
28. Feng L, Xie X, Ding Q, Luo X, He J, Fan F, Liu W, Wang Z and Chen Y. Spatial regulation of Raf kinase signaling by RKTG. Proc Natl Acad Sci U S A 2007; 104: 14348-14353.
29. Luo X, Feng L, Jiang X, Xiao F, Wang Z, Feng GS and Chen Y. Characterization of the topology and functional domains of RKTG. Biochem J 2008; 414: 399-406.
30. Ling ZQ, Guo W, Lu XX, Zhu X, Hong LL, Wang Z and Chen Y. A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers. Ann Oncol 2014; 25: 1363-1372.
31. Tang J, Shen L, Yang Q and Zhang C. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell Prolif 2014; 47: 427-434.
32. Montanaro L, Mazzini G, Barbieri S, Vici M, Nardi-Pantoli A, Govoni M, Donati G, Trere D and Derenzini M. Different effects of ribosome biogenesis inhibition on cell proliferation in retinoblastoma protein- and p53-deficient and proficient human osteosarcoma cell lines. Cell Prolif 2007; 40: 532-549.
33. Obeyesekere MN, Knudsen ES, Wang JY and Zimmerman SO. A mathematical model of the regulation of the G1 phase of Rb+/+ and Rb-/- mouse embryonic fibroblasts and an osteosarcoma cell line. Cell Prolif 1997; 30: 171-194.
34. Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF and Castorina S. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 2014; 47: 435-447.
35. Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, Yang Q, Chan CS and Feng Z. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget 2014; 5: 9106-9117.
36. Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y, Wang K and Wan J. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One 2013; 8: e70300.
37. Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y and Gu X. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One 2012; 7: e29750.
38. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S and Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One 2013; 8: e60155.
39. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M and Iliopoulos D. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147: 1233-1247.
40. Ohno M, Otsuka M, Kishikawa T, Shibata C, Yoshikawa T, Takata A, Muroyama R, Kowatari N, Sato M, Kato N, Kuroda S and Koike K. Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA. Oncotarget 2014; 5: 5581-5590.
41. Lam KL, Yang KL, Sunderasan E and Ong MT. Latex C-serum from Hevea brasiliensis induces non-apoptotic cell death in hepatocellular carcinoma cell line (HepG2). Cell Prolif 2012; 45: 577-585.
42. Chen Y, Hu W, Lu Y, Jiang S, Li C, Chen J, Tao D, Liu Y, Yang Y and Ma Y. A TALEN-based specific transcript knock-down of PIWIL2 suppresses cell growth in HepG2 tumor cell. Cell Prolif 2014; 47: 448-456.
43. Wu HG, Zhang WJ, Ding Q, Peng G, Zou ZW, Liu T, Cao RB, Fei SJ, Li PC, Yang KY, Hu JL, Dai XF, Wu G and Li PD. Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma. Oncol Rep 2014; 32: 2687-2695.
44. Yu L, Zhou L, Cheng Y, Sun L, Fan J, Liang J, Guo M, Liu N and Zhu L. MicroRNA-543 acts as an oncogene by targeting PAQR3 in hepatocellular carcinoma. Am J Cancer Res 2014; 4: 897-906.
45. Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M and Enokida H. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One 2014; 9: e84311.
46. Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, Gui Y and Cai Z. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One 2012; 7: e52280.
47. Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, Tanaka Y, Dahiya R and Yamamura S. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS One 2013; 8: e67686.
48. Xiu Y, Liu Z, Xia S, Jin C, Yin H, Zhao W and Wu Q. MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3. PLoS One 2014; 9: e109734.
49. Xiao X, Tang C, Xiao S, Fu C and Yu P. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res 2013; 20: 537-544.
50. Li J, Martinka M and Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008; 29: 1373-1379.
51. Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Noort PI, Prevost GP, Schaapveld RQ and Cuppen E. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS One 2012; 7: e43569.
52. Xie X, Zhang Y, Jiang Y, Liu W, Ma H, Wang Z and Chen Y. Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse. Carcinogenesis 2008; 29: 1632-1638.
53. Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, Liu C, Song W, Wang F, Zhang J, Shen J and Yu J. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer 2015; 18: 43-54.
54. Yu X and Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med 2014; 34: 923-933.
55. Li Z, Yu X, Shen J, Wu WK and Chan MT. MicroRNA expression and its clinical implications in Ewing's sarcoma. Cell Prolif 2015; 48: 1-6.
56. Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X and Qiu G. MicroRNA-10b Promotes Nucleus Pulposus Cell Proliferation through RhoC-Akt Pathway by Targeting HOXD10 in Intervetebral Disc Degeneration. PLoS One 2013; 8: e83080.
57. Rodriguez-Montes JA and Menendez Sanchez P. Role of micro-RNA in colorectal cancer screening. Cir Esp 2014; 92: 654-8.
58. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG and Yang K. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif 2014; 47: 277-286.
59. Li M, Yu M, Liu C, Zhu H, He X, Peng S and Hua J. miR-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif 2013; 46: 223-231.
60. Ohdaira H, Sekiguchi M, Miyata K and Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif 2012; 45: 32-38.
61. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, Zhang J, Peng C, Lin Y and Chen J. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget 2014; 5: 7013-26.
62. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, de Carvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T and Brodie C. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 2013; 4: 665-676.
63. Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ and Tang CH. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget 2014; 5: 3800-3812.
64. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, Bobbitt K, Rempel SA, Hasselbach L, Mikkelsen T, Slavin S and Brodie C. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget 2013; 4: 346-361.
65. Liu S, An J, Lin J, Liu Y, Bao L, Zhang W and Zhao JJ. Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma. PLoS One 2014; 9: e92791.